Nuvalent (NASDAQ: NUVL) executives highlighted ongoing regulatory milestones for the company's lead oncology programs and discussed commercialization strategy, pipeline plans, and financial positioning during a conference fireside chat. Company focus and lead programs Chief Executive Officer Jim Porter described Nuvalent as a company built around deep chemistry and structure-based drug design expertise, with an emphasis on
CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
Shares of Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) have earned an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating on the company. The average 12-month
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).
Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026 Well capitalized with operating runway anticipated into 2029 Company to present at 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th at 9:00 a.m.
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CFO Alexandra Balcom sold 4,236 shares of Nuvalent stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the sale, the chief financial officer directly owned 84,914 shares of the company's stock, valued
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) insider Deborah Ann Miller sold 4,363 shares of Nuvalent stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total value of $424,607.16. Following the completion of the transaction, the insider directly owned 44,723 shares of the company's
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) insider Christopher Durant Turner sold 4,236 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the transaction, the insider owned 58,311 shares of the company's stock, valued
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CEO James Richard Porter sold 17,890 shares of Nuvalent stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $97.32, for a total transaction of $1,741,054.80. Following the transaction, the chief executive officer directly owned 288,172 shares of the company's stock,
